Home » ACOLOGIX, TOKYO FIRM PARTNER ON DIALYSIS DRUG
ACOLOGIX, TOKYO FIRM PARTNER ON DIALYSIS DRUG
Biopharmaceutical company Acologix said that it is partnering with Toray Industries Inc. to develop and sell a therapeutic drug for dialysis patients in North America and Europe. Hayward-based Acologix has an exclusive license to make and sell the drug in North America. In Europe Acologix and Toray, a Tokyo biopharmaceutical company, will co-develop the drug, and Acologix has a commercialization option. The drug, TRK-820, is designed to treat uremic pruritus, an itching condition that affects dialysis patients and is not responsive to any approved drugs.
San Francisco Business Times (http://www.bizjournals.com/sanfrancisco/stories/2005/06/13/daily39.html?from_rss=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May